Therapeutic approaches in prostatic cancer

Huggins, 1941, Studies on prostatic cancer. I. Effect of castration, estrogen and androgen injections on serum phosphatases in metastatic carcinoma of the prostate, Cancer Res., 1, 293 Bailar, 1970, Vet. Adm. Coop. Urol. Res. Group.: Estrogen treatment for cancer of the prostate, Cancer, 26, 257, 10.1002/1097-0142(197008)26:2<257::AID-CNCR2820260203>3.0.CO;2-9 Murphy, 1980, The questionable use of hormone therapy in advanced carcinoma of the prostate, Urol. Clin. Nth. Am., 7, 631, 10.1016/S0094-0143(21)00151-8 Nesbit, 1950, Endocrine control of prostatic carcinoma: clinical and statistical survey of 1818 cases, J.A.M.A., 143, 1317, 10.1001/jama.1950.02910500019005 Staubiz, 1954, Clinical results of the treatment of prostatic carcinoma over a ten-year period, J. Urol., 72, 939, 10.1016/S0022-5347(17)67697-3 Veterans administration Cooperative Urological Research Group, 1967, Carcinoma of the prostate: treatment comparisons, J. Urol., 98, 516, 10.1016/S0022-5347(17)62926-4 Geller, 1978, Treatment of advanced cancer of the prostate with megestrol acetate, Urology, 12, 537, 10.1016/0090-4295(78)90467-3 Geller, 1981, Medical castration of males with Megestrol acetate and small doses of diethylstilbestrol, J. clin. Endocr. Metab., 52, 576, 10.1210/jcem-52-3-576 Harper, 1974, Plasma steroid and protein hormone concentration in patients with prostatic carcinoma before and during estrogen therapy, Acta endocr. Copenh., 81, 409 Pike, 1970, Testosterone metabolism in vivo by human prostatic tissue, Biochem. J., 120, 443, 10.1042/bj1200443 Resnick, 1975, Treatment of stage IV carcinoma of the prostate, Urol. Clin. Nth. Am., 2, 141, 10.1016/S0094-0143(21)01063-6 Robinson, 1975, The effects of hormonal therapy on plasma testosterone levels in prostatic cancer, Vol. 1, 139 Klosterhalfen, 1975, Recent results of a prospective study of prostatic carcinoma with different types of therapy (estrogens, cortisone, cyproterone acetate, natriureticum and placebo), Vol. I, 193 Geller, 1984, BPH and prostate cancer. Results of hormonal manipulation, Vol. 1, 51 Nesbit, 1946, Prostatic carcinoma: a follow-up of 795 patients treated prior to endocrine era and comparison of survival rate between these and patients treated with endocrine therapy, Surgery, 20, 263 Jacobi, 1980, Treatment of advanced prostatic cancer with parenteral cyproterone acetate: a phase III randomised trial, Br. J. Urol., 52, 208, 10.1111/j.1464-410X.1980.tb02961.x Orestafano, 1975, Mode of action of progesterone, gestonorone caproate (depostat) and cyproterone acetate (Androcur) on the metabolism of testosterone in human prostatic adenoma: in vitro and in vivo investigations, J. steroid Biochem., 6, 845, 10.1016/0022-4731(75)90313-1 Wein, 1973, Experience in the treatment of prostatic carcinoma with cyproterone acetate, J. Urol., 109, 68, 10.1016/S0022-5347(17)60352-5 Geller, 1976, Effect of megestrol acetate (Megace®) on steroid metabolism and steroid protein binding in the human prostate, J. clin. Endocr. Metab., 43, 1000, 10.1210/jcem-43-5-1000 Belanger, 1980, Inhibitory effects of a single intranasal administration of (d-Ser(TBU)6, des-Gly-NH102)LHRH agonist on serum steroid levels in normal adult men, J. steroid Biochem., 13, 123, 10.1016/0022-4731(80)90182-X Faure, 1982, Inhibition of serum androgen levels by chronic intranasal administration of a potent LHRH agonist in adult men, Fert. Steril., 37, 416, 10.1016/S0015-0282(16)46107-8 Labrie, 1982, New hormonal therapy in prostatic carcinoma: combined treatment with LHRH agonist and an antiandrogen, J. clin. Invest. Med., 5, 267 Labrie, 1983, New approach in the treatment of prostate cancer: complete instead of only partial withdrawal of androgens, Prostate, 4, 579, 10.1002/pros.2990040605 Labrie, 1983, New hormonal therapy in prostate cancer: combined use of a pure antiandrogen and an LHRH agonist, Horm. Res., 18, 18, 10.1159/000179775 Labrie, 1983, New hormonal treatment in cancer of the prostate: combined administration of an LHRH agonist and an antiandrogen, J. steroid Biochem., 19, 999, 10.1016/0022-4731(83)90046-8 Labrie, 1984, Dramatic response of prostate cancer to complete antihormonal treatment, Vol. 1, 233 Karr, 1984, Treatment of prostatic carcinoma with combinations of drugs and hormones, 81 Di Silverio, 1968, Il cancro della prostata: nostri orientamenti terapeutici nelle forme estrogeno-resistenti, Boll. Soc. Centro-Meridionale Urol., 5, 161 Sciarra, 1971, Testosterone and Δ4-androstenedione concentrations in peripheral and spermatic venous blood of patients with prostatic adenocarcinoma. Effects of diethylstilbestrol and cyproterone acetate, J. steroid Biochem., 2, 313, 10.1016/0022-4731(71)90019-7 Sciarra, 1973, Plasma testosterone and Δ4-androstenedione after orchidectomy in prostatic adenocarcinoma, Clin. Endocr., 2, 101, 10.1111/j.1365-2265.1973.tb00410.x Bracci, 1975, Our present procedure in the treatment of prostatic cancer, Vol. 1, 177 Bracci, 1977, Hormonal pattern in prostatic carcinoma following orchidectomy: 5 year follow-up, Br. J. Urol., 49, 161, 10.1111/j.1464-410X.1977.tb04092.x Di Silverio, 1978, Sex hormone binding globulin e testosterone libero: modificazioni in corso di terapia ormonale per carcinoma della prostata, Urologia, 45, 1, 10.1177/039156037804500602 Di Silverio, 1978, Testosterone totale, testosterone libero, diidrotestosterone e SHBG nel carcinoma della prostata: modificazioni indotte dalla orchiectomia e dal ciproterone acetato, 1 Di Silverio, 1980, Effetto della orchiectomia, del ciproterone acetato e dell'orchiectomia più ciproterone acetato sui valori plasmatici del testosterone totale, testosterone libero, diidrotestosterone e sex hormone binding globulin in pazienti con carcinoma prostatico, Riv. Oncol., 165 Sciarra, 1981, Plasma testosterone, dihydrotestosterone, androstenedione, 3α- and 3β-androstanediol, free testosterone fraction and sex hormone binding globulin capacity in prostatic adenocarcinoma, Vol. IX, 93 Di Silverio, 1982, Significato prognostico dei livelli plasmatici e tessutali degli ormoni androgeni nel carcinoma prostatico, 14 Di Silverio, 1982, Endocrine control of prostatic cancer: the role of steroid hormone receptors, 49 Concolino, 1982, Steroid receptors and hormone responsiveness of human prostatic carcinoma, Prostate, 3, 475, 10.1002/pros.2990030506 Concolino, 1984, Androgen, estrogen and progesterone receptors in human prostatic carcinoma, 93 Di Silverio, 1975, Histological type of tumor and hormone dependence, 47 Monon, 1977, Androgen receptors in human prostatic tissue: a review, Cancer Treat. Rep., 61, 265 Mobbs, 1978, Androgen receptor assay in human benign and malignant prostatic tumor cytosol using protamine sulphate precipitate, J. steroid Biochem, 9, 289, 10.1016/0022-4731(78)90620-9 Rennie, 1981, Hormone receptors in prostatic tissue, IX, 120 Shain, 1980, Cytoplasmic and nuclear androgen receptor content of normal and neoplastic human prostates and linphonode metastases of human prostatic carcinoma, J. clin. Endocr. Metab., 50, 704, 10.1210/jcem-50-4-704 Hicks, 1979, A microassay for the measurement of androgen receptors in human prostatic tissue, Steroids, 33, 398, 10.1016/0039-128X(79)90014-X Belis, 1981, R.I.A. of tissue steroids in adenocarcinoma of the prostate, Cancer, 48, 2416, 10.1002/1097-0142(19811201)48:11<2416::AID-CNCR2820481113>3.0.CO;2-W Krieg, 1979, A comparative study of binding metabolism and endogenous levels of androgens in normal, hyperplastic and carcinomatous human prostate, J. steroid Biochem., 11, 615, 10.1016/0022-4731(79)90090-6 Morioka, 1982, Endogenous androgen levels in human prostatic tissues, Folia Endocr. Jap., 58, 876, 10.1507/endocrine1927.58.7_876 Verdonck, 1980, Subcellular distribution of androgens in hyperplastic human prostate, J. steroid Biochem., 13, 607, 10.1016/0022-4731(80)90026-6 Geller, 1979, Steroid levels in cancer of the prostate, markers of tumor differentiation and adequacy of antiandrogen therapy, J. steroid Biochem., 11, 631, 10.1016/0022-4731(79)90092-X Geller, 1978, Dihydrotestosterone concentration in prostate cancer tissue as a predictor of tumor differentiation and hormonal dependency, Cancer Res., 38, 4349 Hammond, 1978, Endogenous steroid levels in the human prostate from birth to old age: a comparison of normal and diseased tissue, J. Endocr., 78, 7, 10.1677/joe.0.0780007 Sciarra, 1982, I metaboliti 5α-ridotti del testosterone nell'ipertrofia prostatica, J. Endocr. Invest., 5, 126 Geller, 1984, Tissue dihydrotestosterone levels and clinical response to hormonal therapy in patients with advanced prostate cancer, J. clin. Endocr. Metab., 58, 36, 10.1210/jcem-58-1-36 Lasnitzki, 1979, Metabolism and action of steroid hormones on human benign prostatic hyperplasia and prostatic carcinoma grown in organ culture, J. steroid Biochem., 11, 625, 10.1016/0022-4731(79)90091-8 Walsh, 1983, Tissue content of dihydrotestosterone in human prostatic hyperplasia is not supranormal, J. clin. Invest., 72, 1772, 10.1172/JCI111137 Tribukait, 1980, Tumor ploidy for characterization of prostatic carcinoma: Flow-cytometric DNA studies using aspiration biopsy material, J. Urol. Nephrol., 59 Fukimoto, 1985, An evaluation of cellular DNA content in prostate cancer, J. Urol., 270, 805 Chin, 1985, Relationship between DNA-ploidy, glandular differentiation and tumor spread in human prostate cancer, J. Urol., 201, 351 Mostofi, 1975, Grading of prostatic carcinoma, Cancer Chemiother. Tep., 59, 111 Murphy, 1983, Treatment of newly diagnosed metastatic prostate cancer patients with chemotherapy agents in combination with hormones versus hormones alone, Cancer, 51, 1264, 10.1002/1097-0142(19830401)51:7<1264::AID-CNCR2820510716>3.0.CO;2-U Concolino, 1980, Steroid receptors and endocrine therapy of prostatic carcinoma, 202 Toscano, 1981, Simultaneous determination of 5α-reduced metabolites of testosterone in human plasma, J. steroid Biochem., 6, 574, 10.1016/0022-4731(81)90033-9 Teodori, 1984, Cytometrically determined relative DNA content as an indicator of neoplasia in gastric lesions, Cytometry, 5, 63, 10.1002/cyto.990050110 Wenderoth, 1984, Hormonal and anti-hormonal treatment of advanced prostatic carcinoma, 77 de Voogt, 1978, Steroid receptors in human prostatic cancer: a preliminary evaluation, Urol. Res., 6, 151, 10.1007/BF00261316 Wagner, 1978, Clinical relevance of androgen receptor content in human prostatic carcinoma, Acta endocr., Copenh., 139 Trachtenberg, 1982, Correlation of prostatic nuclear androgen receptor content with duration of response and survival following hormonal therapy in advanced prostatic cancer, J. Urol., 127, 466, 10.1016/S0022-5347(17)53868-9 Ghanadian, 1981, Predicting the response of prostatic carcinoma to endocrine therapy, The Lancet, II, 1418, 10.1016/S0140-6736(81)92829-4